Media continue to cover a study led by Alison Edelman, M.D., and team that revealed a flu vaccine, either given alone or with a COVID-19 vaccine during the follicular phase, was linked to minor changes in the length of the menstrual cycle of less than one day, but the length of the cycle bounced back to normal soon after.

Former OHSU oncologist Vinay Prasad tapped by RFK Jr. to head FDA vaccine division.

The OHSU Knight Cancer Institute mobile unit participated in a community cancer conversation hosted by Evergreen Family Medicine May. 8. OHSU experts collaborated with community organizations to provide information and education on when to get cancer screening, lifestyle changes for cancer prevention, and skin cancer awareness.

Continued coverage of research led by Jamie Lo, M.D., M.C.R., and published in JAMA Pediatrics that found consuming cannabis while pregnant appears to increase the odds of preterm birth, low birth weight and infant death; Lo says: “The most striking finding is the increased risk of perinatal mortality — death either during the pregnancy or shortly after the pregnancy.”

Continued coverage of research led by Jamie Lo, M.D., M.C.R., and published in JAMA Pediatrics that found consuming cannabis while pregnant appears to increase the odds of preterm birth, low birth weight and infant death; Lo says: “The most striking finding is the increased risk of perinatal mortality — death either during the pregnancy or shortly after the pregnancy.”

The proposed merger of Legacy Health and Oregon Health & Science University will not move forward.

OHSU, Legacy Health agree to terminate plans to integrate organizations.

Brain & Life magazine interviews David Spencer, M.D., regarding new guidelines about when people with epilepsy can obtain a driver’s license and resume driving: “A uniform approach across the country is recommended, rather than the current patchwork of rules based on what state you live in.”

OHSU and the University of Michigan receive $2.8 million from the Juvenile Diabetes Foundation to expand the existing Breakthrough T1D Center of Excellence at the University of Michigan and establish an innovative clinical trial that tests promising heart and kidney therapies in people with type 1 diabetes.